Print  |  Close

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)


Active: Yes
Cancer Type: Multiple Myeloma NCT ID: NCT03374085
Trial Phases: Phase I
Phase II
Protocol IDs: CC-92480-MM-001 (primary)
NCI-2018-00132
U1111-1205-3650
2017-001236-19
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Celgene
NCI Full Details: http://clinicaltrials.gov/show/NCT03374085

Summary

This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK
and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with
relapsed and refractory multiple myeloma (RRMM).

RRMM patient previously treated with at least 3 prior regimens including lenalidomide or
pomalidomide, a proteasome inhibitor and a CD38 antibody will be eligible.

Treatment Sites in Georgia

Emory Clinic
1365 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.